JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
1.0
Cite Score 2025
SJR: 0.129 / SNIP: 0.140
Volume 18, Issue 2 (2026)
Iran J War Public Health 2026, 18(2): 201-206 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2026/04/3 | Accepted: 2026/06/17 | Published: 2026/06/21
Received: 2026/04/3 | Accepted: 2026/06/17 | Published: 2026/06/21
How to cite this article
Jasim A, Ali B, Abdulbaqi M. CD35 Protein-Gene as a Diagnostic Biochemical of Iraqi Hepatic Cancer Patients. Iran J War Public Health 2026; 18 (2) :201-206
URL: http://ijwph.ir/article-1-1760-en.html
URL: http://ijwph.ir/article-1-1760-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Community Health Department, Polytechnic College-Karbala, Al-Furat Al-Awsat Technical University, Kufa, Iraq
2- Medical Laboratories Department, Polytechnic College-Karbala, Al-Furat Al-Awsat Technical University, Kufa, Iraq
2- Medical Laboratories Department, Polytechnic College-Karbala, Al-Furat Al-Awsat Technical University, Kufa, Iraq
Abstract (1301 Views)
Aims: CD35, a gene encoding a key protein involved in inflammation and immune regulation, has been implicated in the development of several cancers. This study aimed to investigate the relationship between CD35 tag single-nucleotide polymorphisms and susceptibility to hepatic carcinoma, as well as their potential association with postoperative recurrence, thereby contributing to a better understanding of gene–environment interactions in hepatic carcinoma.
Materials & Methods: This hospital-based observational study included 120 Iraqi participants, comprising 56 patients with hepatic carcinoma and 64 healthy controls. The study investigated whether CD35 tag single-nucleotide polymorphisms were associated with susceptibility to hepatic carcinoma and, among patients who underwent surgery, with postoperative recurrence. Three CD35 tag single-nucleotide polymorphisms—rs2296160, rs3849266, and rs7525160—were selected using HaploView version 4.2 and genotyped using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS).
Findings: Among 56 patients with hepatic carcinoma and 64 controls, CD35 rs2296160 and rs3849266 showed no significant genotype differences between groups (p>0.05). In contrast, rs7525160 was associated with hepatic carcinoma.The rs7525160 C-allele association was more evident in patients with tumors >5cm, TNM stage III/IV disease, cirrhosis, portal vein thrombosis, or AFP >400ng/mL. There was an association between the CC/CG genotype and postoperative recurrence; however, the hazard ratio and 95% confidence interval should be added.
Conclusion: Among Iraqi participants younger than 65 years, the CD35 rs7525160 polymorphism increases hepatic carcinoma susceptibility and predicts poorer recurrence-free survival.
Materials & Methods: This hospital-based observational study included 120 Iraqi participants, comprising 56 patients with hepatic carcinoma and 64 healthy controls. The study investigated whether CD35 tag single-nucleotide polymorphisms were associated with susceptibility to hepatic carcinoma and, among patients who underwent surgery, with postoperative recurrence. Three CD35 tag single-nucleotide polymorphisms—rs2296160, rs3849266, and rs7525160—were selected using HaploView version 4.2 and genotyped using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS).
Findings: Among 56 patients with hepatic carcinoma and 64 controls, CD35 rs2296160 and rs3849266 showed no significant genotype differences between groups (p>0.05). In contrast, rs7525160 was associated with hepatic carcinoma.The rs7525160 C-allele association was more evident in patients with tumors >5cm, TNM stage III/IV disease, cirrhosis, portal vein thrombosis, or AFP >400ng/mL. There was an association between the CC/CG genotype and postoperative recurrence; however, the hazard ratio and 95% confidence interval should be added.
Conclusion: Among Iraqi participants younger than 65 years, the CD35 rs7525160 polymorphism increases hepatic carcinoma susceptibility and predicts poorer recurrence-free survival.
Keywords:
Proteins [MeSH], Genetic Variation [MeSH], Metastasis [MeSH], Disease Susceptibility [MeSH], Hepatic Cancer [MeSH]
References
1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. [Link] [DOI:10.1038/s41575-019-0186-y]
2. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-48. [Link] [DOI:10.1001/jamaoncol.2016.5688]
3. Ding C, Fu X, Zhou Y, Liu X, Wu J, Huang C, et al. Disease burden of liver cancer in China from 1997 to 2016: An observational study based on the Global Burden of Diseases. BMJ Open. 2019;9(4):e025613. [Link] [DOI:10.1136/bmjopen-2018-025613]
4. ChenW, Zheng R, Baade PD, Zhang S, ZengH, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32. [Link] [DOI:10.3322/caac.21338]
5. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis. Am J Gastroenterol. 2016;111(11):1573-80. [Link] [DOI:10.1038/ajg.2016.330]
6. Chayanupatkul M, Omino R, Mittal S, Kramer JR, Richardson P, Thrift AP, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017;66(2):355-62. [Link] [DOI:10.1016/j.jhep.2016.09.013]
7. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. [Link] [DOI:10.1002/hep.28431]
8. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369-80. [Link] [DOI:10.1016/j.cgh.2005.12.007]
9. Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, et al. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun. 2018;2(6):747-59. [Link] [DOI:10.1002/hep4.1182]
10. Zhang C, Ye Z, Zhang Z, Zheng J, Tang Y, Hou E, et al. A comprehensive evaluation of single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Asian populations: A systematic review and network meta-analysis. Gene. 2020;735:144365. [Link] [DOI:10.1016/j.gene.2020.144365]
11. Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, Cultraro CM, et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology. 2010;52(6):2034-43. [Link] [DOI:10.1002/hep.23943]
12. Liu F, Li F, Luo L, Yang H, Wei Y, Wang W, et al. Genetic variants in cell death pathway genes and HBV-related hepatocellular carcinoma among a Chinese Han population. Apoptosis. 2017;22(8):1035-47. [Link] [DOI:10.1007/s10495-017-1385-z]
13. Jasim AH, Altememy D. Comparison of chemotherapy effectiveness between cancer patients with and without dependent dose of radiotherapy. Iran J War Public Health. 2024;16(3):289-94. [Link]
14. Shen FM, Lee MK, Gong HM, Cai XQ, King MC. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: Interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet. 1991;49(1):88-93. [Link]
15. An P, Xu J, Yu Y, Winkler CA. Host and viral genetic variation in HBV-related hepatocellular carcinoma. Front Genet. 2018;9:261. [Link] [DOI:10.3389/fgene.2018.00261]
16. Sunyer JO, Zarkadis IK, Lambris JD. Complement diversity: A mechanism for generating immune diversity?. Immunol Today. 1998;19(11):519-23. [Link] [DOI:10.1016/S0167-5699(98)01341-3]
17. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res. 2010;8(11):1453-65. [Link] [DOI:10.1158/1541-7786.MCR-10-0225]
18. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009;30(6):286-92. [Link] [DOI:10.1016/j.it.2009.04.002]
19. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: Untangling an intricate relationship. Nat Rev Immunol. 2018;18(1):5-18. [Link] [DOI:10.1038/nri.2017.97]
20. Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. 2006;3(5):333-40. [Link]
21. Thorgersen EB, Barratt-Due A, Haugaa H, Harboe M, Pischke SE, Nilsson PH, et al. The role of complement in liver injury, regeneration, and transplantation. Hepatology. 2019;70(2):725-36. [Link] [DOI:10.1002/hep.30508]
22. Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479-92. [Link] [DOI:10.1016/j.semnephrol.2013.08.001]
23. Krych-Goldberg M, Atkinson JP. Structure-function relationships of complement receptor type 1. Immunol Rev. 2001;180(1):112-22. [Link] [DOI:10.1034/j.1600-065X.2001.1800110.x]
24. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-97. [Link] [DOI:10.1038/ni.1923]
25. Yu X, Rao J, Lin J, Zhang Z, Cao L, Zhang X. Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer. Mol Cancer. 2014;13:56. [Link] [DOI:10.1186/1476-4598-13-56]
26. He JR, Xi J, Ren ZF, Qin H, Zhang Y, Zeng YX, et al. Complement receptor 1 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2012;13(12):6527-31. [Link] [DOI:10.7314/APJCP.2012.13.12.6527]
27. Srivastava A, Mittal B. Complement receptor 1 (A3650G RsaI and Intron 27 HindIII) polymorphisms and risk of gallbladder cancer in North Indian population. Scand J Immunol. 2009;70(6):614-20. [Link] [DOI:10.1111/j.1365-3083.2009.02329.x]
28. Luo L, Li Q, Su Z, Li L, Cai B, Peng Y, et al. Genetic polymorphisms in CD35 gene contribute to the susceptibility and prognosis of hepatocellular carcinoma. Front Oncol. 2021;11:700711. [Link] [DOI:10.3389/fonc.2021.700711]
29. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. [Link]
30. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. [Link]
31. Al-Joda BM, Jasim AH. A comparative evaluation of calcitonin and carcinoembryonic antigen levels with chemotherapy for gastrointestinal cancer patients in Kerbala governorate. Int J Drug Deliv Technol. 2021;11(1):106-8. [Link]
32. Pasic I, Wong KM, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, et al. Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. Mol Carcinog. 2018;57(1):106-13. [Link] [DOI:10.1002/mc.22736]